ICM
NKTR icon

IronBridge Capital Management’s Nektar Therapeutics NKTR Stock Holding History

IronBridge Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-37,759
Closed -$5.92M – 216
2013
Q3 		$5.92M Sell
37,759
-16,875
-31% -$3.12M 0.13% 158
2013
Q2 		$9.46M Buy
+54,634
New +$8.38M 0.19% 163

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

IronBridge Capital Management's NKTR Position: Q4 2013 in Review

IronBridge Capital Management sold out of Nektar Therapeutics (NKTR) in Q4 2013, closing a stake of 37,759 shares — an estimated $5.92M sold.

IronBridge Capital Management first reported a position in NKTR in Q2 2013 and held it in 2 quarters. The position peaked at $9.46M in Q2 2013. 136 funds tracked by Wall St. Rank hold NKTR as of Q4 2013.

  • IronBridge Capital Management reported no remaining Nektar Therapeutics position as of Q4 2013 after selling out during the quarter.
  • IronBridge Capital Management sold 37,759 Nektar Therapeutics shares in Q4 2013, an estimated $5.92M.
  • IronBridge Capital Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 2 quarters.
  • IronBridge Capital Management's Nektar Therapeutics position peaked at $9.46M in Q2 2013.
  • 136 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2013.

Based on IronBridge Capital Management's 13F filing for Q4 2013, filed 11 Feb 2014.